A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin

2 1 1

What is this study about?

This study involves patients with Merkel cell carcinoma, which is a rare and aggressive type of skin cancer. The study will test a treatment called Cemiplimab, which is also known by its code name REGN2810. This medication is a type of drug that works by blocking a protein called PD-1, which can help the body’s immune system fight cancer cells. Some patients in the study will receive Cemiplimab while others will receive a placebo. The medication will be given through an infusion into a vein, and patients will receive up to 700 milligrams over the course of their treatment.

The purpose of this study is to evaluate how well Cemiplimab works when given before a procedure called a sentinel lymph node biopsy, which is a test to check if cancer has spread to nearby lymph nodes. The study will measure whether this treatment helps prevent the presence of tiny cancer spread in the lymph nodes. Patients in this study will have already had their primary tumor removed and will be scheduled for the lymph node biopsy. The study will also look at how long patients remain free from cancer coming back, how long patients survive, and how the treatment affects their quality of life.

During the study, patients will receive two cycles of treatment before their lymph node biopsy. The study will collect tissue samples from the original tumor site and from the lymph node biopsy to examine how the treatment affects the cancer. Safety will be monitored throughout the study by tracking any side effects that occur. The study will also compare outcomes between patients who receive Cemiplimab and those who receive placebo, looking at factors such as whether cancer returns, survival rates, and overall well-being using questionnaires.

1 Initial treatment phase

After joining the study, you will receive either cemiplimab or a placebo (an inactive substance). This is a double-blind study, which means neither you nor your doctor will know which treatment you are receiving.

Cemiplimab is a type of medication called a PD-1 inhibitor, which works by helping your immune system fight cancer cells.

The treatment will be given intravenously, meaning through a vein in your arm.

You will receive 2 cycles of treatment before the next procedure.

2 Sentinel lymph node biopsy

After completing the 2 cycles of treatment, you will undergo a sentinel lymph node biopsy.

A sentinel lymph node biopsy is a procedure where the first lymph node to which cancer cells are likely to spread from the primary tumor is removed and examined.

The tissue samples from your primary tumor and the lymph node will be analyzed for the study.

3 Follow-up period

After the sentinel lymph node biopsy, you will enter a follow-up period where your health will be monitored.

During this period, assessments will be made to check for any signs of cancer returning or progressing.

Your quality of life will be evaluated using questionnaires throughout the study.

4 Safety monitoring

Throughout the entire study, any side effects or health changes you experience will be recorded and evaluated.

This monitoring will continue during and after your treatment to ensure your safety.

Who Can Join the Study?

You must have signed a written consent form agreeing to participate in the study.
You must be 18 years old or older at the time you sign the consent form.
You must have been diagnosed with Merkel cell carcinoma, which is a rare type of skin cancer. Your cancer should be in clinical stage II, or in stage I with a tumor size of at least 1 centimeter. The main tumor must have already been removed by surgery, and you must still be scheduled to have a sentinel lymph node biopsy, which is a procedure to check if cancer has spread to nearby lymph nodes.
Your ECOG performance status must be between 0 and 2. This is a scale that measures how well you can perform daily activities, where 0 means you are fully active and 2 means you can care for yourself but cannot work.
Your blood test results must meet certain requirements:
- Your neutrophil count (a type of white blood cell that fights infection) must be at least 1.5 x 10⁹ per liter.
- Your platelet count (cells that help blood clot) must be at least 75 x 10⁹ per liter.
- Your hemoglobin level (a protein in red blood cells that carries oxygen) must be at least 9 grams per deciliter.
- Your total bilirubin (a substance produced when red blood cells break down) must not be more than 1.5 times the upper normal limit. If you have Gilbert’s Disease, a harmless liver condition, you may be eligible with bilirubin up to 3 times the upper limit after approval.
- Your AST and ALT (liver enzymes that show how well your liver is working) must not be more than 3 times the upper normal limit.
- Your alkaline phosphatase (an enzyme found in the liver and bones) must not be more than 2.5 times the upper normal limit.
- Your serum creatinine (a waste product that shows how well your kidneys are working) must not be more than 2 times the upper normal limit, or your creatinine clearance (a measure of kidney function) must be at least 40 milliliters per minute.
If you are a woman who can become pregnant, or a man with a female partner who can become pregnant, you must agree to either avoid sexual intercourse or use highly effective birth control methods with less than 1% failure rate during treatment and for at least 6 months after receiving the last dose of the study medication. Men must also agree not to donate sperm during this time. Men with pregnant partners must agree to avoid sexual intercourse or use condoms throughout the pregnancy.
You must be willing to allow researchers to use your tissue samples from the removed tumor and the sentinel lymph node biopsy for research purposes.

Who Cannot Join the Study?

The source data does not provide specific exclusion criteria (reasons why patients cannot participate) for this clinical trial
Exclusion criteria are conditions or factors that would prevent someone from joining a study, but these details are not available in the provided information
Without this information, it is not possible to list the specific reasons that would make a patient ineligible for this particular study

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz	Mainz	Germany
Universitaetsklinikum Heidelberg AöR	Heidelberg	Germany
Universitaet Leipzig	Leipzig	Germany

Other Sites

Site Name	City	Country
HELIOS Klinikum Erfurt GmbH	Erfurt	Germany
Muehlenkreiskliniken AöR	Minden	Germany
Klinikum Bielefeld gGmbH	Bielefeld	Germany
Universitaetsklinikum Regensburg AöR	Regensburg	Germany
Universitaetsklinikum Tuebingen AöR	Tuebingen	Germany
Uvuuwrysgt Mpekgdg Cnyhwv Hmovorsidjkaquctc	Hamburg	Germany
Ugwlploovlcunecieyicc Ewcbw Afw	Essen	Germany
Uizqjogldm Hrlthjpx Csvrzku	Cologne	Germany
Gydpki Ugulyywbsq Fgchscxzj	Frankfurt	Germany
Ulgwvuzilygzxajhwbbjw Wxirqizfr Aig	Wuerzburg	Germany

Trial status

Country	Status	Recruitment Start
Germany	Recruiting	01.12.2025

Trial locations

Investigated drugs:

Cemiplimab

Cemiplimab is a type of immunotherapy medication that works by helping your immune system fight cancer. It blocks a protein called PD-1 on immune cells, which allows your body’s natural defenses to recognize and attack cancer cells more effectively. In this study, it is being tested as a treatment given before surgery in patients with Merkel cell carcinoma, which is a rare type of skin cancer.

Placebo is an inactive substance that looks like the real medication but contains no active treatment. It is used in research studies to compare the effects of the actual medication against no treatment, helping researchers understand if the medication is truly effective.

Investigated diseases:

Neuroendocrine carcinoma of the skin

Merkel Cell Carcinoma – Merkel cell carcinoma is a rare and aggressive type of skin cancer that develops in Merkel cells, which are found in the top layer of the skin near nerve endings. The disease typically appears as a firm, painless nodule or lump on sun-exposed areas of the body, such as the head, neck, or arms. The tumor usually grows rapidly and has a flesh-colored, red, or bluish appearance. As the disease progresses, the cancer cells can spread to nearby lymph nodes in the region. If left untreated, the cancer may continue to spread to other lymph nodes and distant organs throughout the body. The disease is more common in older adults and people with weakened immune systems.

Trial ID:

2025-522091-84-00

Protocol code:

NeoMatryx

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?